（文章来源：证券日报） 证券日报网讯 9月22日晚间，戴维医疗发布公告称，公司全资孙公司宁波甬星医疗仪器有限公司因业务 发展需要，变更经营范围，于近日完成了工商变更登记手续，并取得了由象山县市场监督管理局核准颁 发的新的《营业执照》。 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-049 宁波戴维医疗器械股份有限公司 关于全资孙公司完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司全资孙公司宁波甬星医疗仪器 有限公司（以下简称"甬星医疗"）因业务发展需要，变更经营范围， 于近日完成了工商变更登记手续，并取得了由象山县市场监督管理局 核准颁发的新的《营业执照》，具体内容如下： 统一社会信用代码：91330212728102683L 名称：宁波甬星医疗仪器有限公司 类型：有限责任公司（自然人投资或控股的法人独资） 住所：浙江省宁波市象山县石浦镇科技园区科苑路2号 法定代表人：汪长江 注册资本：捌佰万元整 成立日期：2001年04月27日 经营范围：许可项目：第二类医疗器械生产；医疗器械互联网信 息服务（依法须经批准的项目，经相关部门批准后方可开展经营活动， 具体经营项目以审批结果为准）。一般项目：金属切削机床销售；第 二类医疗器械销售；模具销售；机械零件、零部件销售；塑料制品销 售；电子元器件与机电组件设备销售；互联网销售（除销 ...

证券日报网讯 9月17日晚间，戴维医疗发布公告称，公司于近日取得由浙江省药品监督管理局颁发的1 项《医疗器械注册证》，公司产品新生儿专用监护仪完成了延续注册。 （文章来源：证券日报） ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江省药品监督管理局颁发的1项《医疗器械注册证》，公司产品新生儿 专用监护仪完成了延续注册，具体如下： 证券代码：300314 证券简称：戴维医疗 公告编号：2025-048 宁波戴维医疗器械股份有限公司 关于公司部分医疗器械产品完成延续注册的公告 本次延续注册的完成，使得公司可以继续生产和销售新生儿专用监护 仪，对公司未来经营将产生积极影响。上述产品的实际销售情况取决于未 来市场推广效果，公司目前尚无法预测其对公司未来业绩的影响，敬请投 资者注意投资风险。 特此公告。 宁波戴维医疗器械股份有限公司 | 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 新生儿专用监 | 浙械注准 | 2031.3.23 | Ⅱ类 | 产品适用于医疗机构 | | | 护仪 | 20212070101 | | | 对新生儿患者进行心 | | | | ...

Core Viewpoint - David Medical's stock has experienced fluctuations, with a recent decline despite a year-to-date increase, indicating potential volatility in the market [1][2]. Company Overview - David Medical, established on September 18, 1992, and listed on May 8, 2012, is located in Xiangshan, Ningbo, Zhejiang Province. The company specializes in the research, production, and sales of infant care equipment [2]. - The main revenue sources are: 51.93% from obstetric and pediatric care equipment, 45.88% from minimally invasive surgical instruments, and 2.18% from other products [2]. Stock Performance - Year-to-date, David Medical's stock price has increased by 31.03%. However, it has seen a decline of 3.17% over the last five trading days and 1.61% over the last 20 days. In contrast, the stock rose by 21.36% over the past 60 days [2]. - As of September 15, the stock price was reported at 14.64 CNY per share, with a market capitalization of 4.216 billion CNY [1]. Financial Performance - For the first half of 2025, David Medical reported a revenue of 251 million CNY, a year-on-year decrease of 5.48%. However, the net profit attributable to shareholders increased by 9.57% to 50.9767 million CNY [2]. Shareholder Information - As of August 29, the number of shareholders was 22,400, a decrease of 2.18% from the previous period. The average number of circulating shares per person increased by 2.23% to 6,417 shares [2]. - The company has distributed a total of 342 million CNY in dividends since its A-share listing, with 120 million CNY distributed in the last three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Ling Huo Pei Zhi Mixed Fund (004685) is the fourth largest with 900,000 shares, and Yuan Xin Yong Feng Ju You A (010469) is the fifth largest with 882,000 shares, both being new shareholders [3].

证券代码：300314 证券简称：戴维医疗 公告编号：2025-047 宁波戴维医疗器械股份有限公司 关于全资子公司医疗器械注册证变更的公告 宁波戴维医疗器械股份有限公司 董事会 2025年9月12日 一、医疗器械注册证变更具体情况 | | 一次性使用管型吻合 | 浙械注准 20152020237 | Ⅱ类 | 因材料变更等涉及的产 | | --- | --- | --- | --- | --- | | 序号 1 | 产品名称 器 | 注册证编号 | 注册分类 | 主要变更内容 品技术要求变更 | 二、对公司的影响及风险提示 上述医疗器械注册证"产品技术要求"的变更，符合公司的生产经营 实际，对公司发展具有积极影响，但尚无法预测上述变更事宜对公司未来 营业收入的影响，敬请广大投资者予以关注并注意投资风险。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司于近日取得由浙江省药品监督管理局颁发 的《中华人民共和国医疗器械变更注册（备案）文件》，公司产品一次性 使用管 ...

Core Viewpoint - Jin Hai Medical Technology (02225) experienced a significant stock price increase of over 41% in the afternoon trading session, with a cumulative rise exceeding 80% post-earnings announcement, despite reporting a substantial decline in revenue and an increase in shareholder losses [1] Financial Performance - The company reported a revenue of 14.529 million Singapore dollars, representing a year-on-year decrease of 43.98% [1] - Shareholder losses amounted to 10.253 million Singapore dollars, which is a year-on-year increase of 69.67% [1] Capital Raising and Use of Proceeds - The company announced a plan to issue 120 million new shares, which will represent approximately 2.27% of the enlarged share capital [1] - The net proceeds from this issuance are expected to be around 161 million Hong Kong dollars, intended for potential acquisitions in the healthcare sector, research and development expenses, and general working capital [1] Strategic Partnerships - On July 2, the company's wholly-owned subsidiary, Shanghai Jin Hai Medical Technology Co., Ltd., entered into a five-year cooperation framework agreement with Ningbo David Medical Instruments Co., Ltd. [1] - This agreement aims to collaborate on endoscope products in the international market, focusing on creating competitive high-end medical device solutions [1]

Group 1 - The company announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., has completed the registration procedures for changing its business scope due to business development needs [2] - The new business license has been approved and issued by the Ningbo Market Supervision Administration [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司全资子公司宁波维尔凯迪医疗 器械有限公司（以下简称"维尔凯迪"）因业务发展需要，变更经营 范围，于近日完成了工商变更登记手续，并取得了由宁波市市场监督 管理局核准颁发的新的《营业执照》，具体内容如下： 统一社会信用代码：91330201750371740P 证券代码：300314 证券简称：戴维医疗 公告编号：2025-046 宁波戴维医疗器械股份有限公司 名称：宁波维尔凯迪医疗器械有限公司 关于全资子公司完成工商变更登记的公告 类型：有限责任公司（自然人投资或控股的法人独资） 2025年9月5日 住所：宁波市科技园区菁华路100号 法定代表人：陈再宏 注册资本：捌仟万元整 成立日期：2003年07月01日 经营范围：一般项目：第一类医疗器械销售；第一类医疗器械生 产；第二类医疗器械销售；电子元器件制造；技术服务、技术开发、 技术咨询、技术交流、技术转让、技术推广；货物进出口；技术进出 口（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 许可项目：第二类医疗器械生产；第三类 ...

Group 1 - The core viewpoint of the article is that David Medical (300314.SZ) has received FDA certifications for some of its products, although none have been exported to the United States yet [1]